Choosing a Clinical Trial for Anaplastic Astrocytoma: How to Match Your Grade III Tumor's Mutations to the Right Study

What Anaplastic Astrocytoma Means Under the 2021 WHO Classification

Anaplastic astrocytoma is a high-grade brain tumor that grows from star-shaped glial cells called astrocytes. The 2021 World Health Organization (WHO) classification changed how these tumors are graded. Today, a tumor's grade depends on both how its cells look under a microscope and on its genetic makeup.

Under WHO 2021, an IDH-mutant astrocytoma with a homozygous deletion of CDKN2A/B is automatically classified as grade IV regardless of how the cells appear. If your pathology report reads anaplastic astrocytoma, IDH-mutant, CNS WHO grade 3, it means your tumor carries an IDH mutation but does not carry that CDKN2A deletion. That single distinction can open or close trial doors, so confirm this with your neuropathologist.

Most adult anaplastic astrocytomas carry an IDH mutation. These tumors have better biology than IDH-wildtype tumors of the same grade, according to the National Brain Tumor Society.

Why Your Tumor's Mutation Profile Drives Trial Matching

Every clinical trial lists eligibility criteria: the specific molecular features your tumor must have for you to enroll. Matching those criteria to your pathology report is the first and most important step in any trial search.

These are the key markers to locate in your report:

• IDH1 or IDH2 mutation: The defining marker of this tumor type. Most adult anaplastic astrocytomas carry IDH1 R132H. IDH2 variants and other IDH1 point mutations are less common but equally important. Many open trials require IDH mutations.
• ATRX loss: Found in most IDH-mutant astrocytomas. ATRX loss is linked to alternative lengthening of telomeres, a way tumor cells keep chromosome ends long without normal telomerase activity. Some trials check for ATRX status.
• TP53 mutation: Often appears with IDH mutation and ATRX loss. It is rarely a standalone trial target in glioma today, but some studies use it to decide which treatment group you join.
• MGMT promoter methylation: This silencing mark on a DNA repair gene predicts how well a tumor responds to temozolomide. It matters for standard treatment choices and some combination trials. For more details, see MGMT Methylation and Temozolomide Response.
• TERT promoter mutation: More common in IDH-wildtype glioblastoma, but found in some grade III astrocytomas. A few trials use TERT status to assign patients to different treatment groups.
• CDKN2A/B status: Under WHO 2021, homozygous deletion upgrades a tumor to grade IV. If your report does not mention CDKN2A, ask your neuropathologist if it was tested. This matters before you look at grade-specific trials.
• 1p/19q co-deletion (absent): Anaplastic astrocytoma lacks 1p/19q co-deletion, which tells it apart from anaplastic oligodendroglioma. Some trials include or exclude patients based on this status.

Clinical trials now use molecular markers as eligibility criteria as standard practice in high-grade glioma research, according to the NCI's Adult Brain Tumor Treatment guidelines.

For a broader introduction to molecular profiling, see What Molecular Tests Does Your Newly Diagnosed Glioblastoma Actually Need. Though that article focuses on glioblastoma, much of the testing framework applies to grade III astrocytoma as well.

The Standard-of-Care Context

Before looking at trials, know what standard treatment involves. Most patients with anaplastic astrocytoma have surgery to remove as much tumor as safely possible, followed by radiation with temozolomide chemotherapy during and after radiation. The CATNON trial showed that temozolomide after radiotherapy helps IDH-mutant, 1p/19q-intact grade III gliomas.

Clinical trials for this diagnosis generally fall into three groups: a new agent or approach added alongside active chemoradiation, a replacement for one standard element, or a maintenance therapy studied after standard treatment ends. Knowing where you are in treatment helps you find the right trials for your situation.

For a detailed look at why surgical resection alone is not enough for this diagnosis, see Why Does Surgery Alone Fail for Anaplastic Astrocytoma?

IDH Inhibitors: The Most Molecularly Targeted Approach

The IDH mutation is the most actionable marker in anaplastic astrocytoma. Mutant IDH1 and IDH2 enzymes produce an oncometabolite called 2-hydroxyglutarate that changes epigenetic signaling and drives tumor growth. Small-molecule IDH inhibitors block this pathway by targeting the mutant enzyme directly.

Vorasidenib (Voranigo) is an oral dual inhibitor of mutant IDH1 and IDH2 that reaches the brain well. It received FDA approval in August 2024 for grade 2 astrocytoma and oligodendroglioma based on the INDIGO trial. That approval covers grade 2, not grade 3. The NCI's overview of vorasidenib in low-grade glioma explains how this drug class works and what the INDIGO data showed.

A Phase III trial called VIGOR (NCT06809322) started enrolling in January 2026. It tests vorasidenib as follow-up therapy in patients with IDH-mutant grade 2 or grade 3 astrocytoma who have completed first-line chemoradiotherapy. If you're near the end of standard treatment, ask your neuro-oncologist about the VIGOR trial. The primary completion date is April 2035, so enrollment is active.

Immunotherapy Trials That Use the IDH Mutation as a Target

Some immunotherapy studies use the IDH1 R132H mutation as a tumor-specific neoantigen: a protein the immune system does not encounter on healthy brain cells. Early studies of an IDH1 R132H peptide vaccine (NCT02454634) tested whether training the immune system against this mutation-specific protein could trigger an anti-tumor response in patients with IDH-mutant grade III and IV gliomas, including those with ATRX loss.

New CAR-T cell trials target antigens such as IL13Ra2 and EGFR in patients with IDH-mutant high-grade gliomas, including recurrent grade III disease. Eligibility for these studies may require tumor antigen expression testing, which your neuropathology team can help arrange. If your molecular profile includes PTEN loss or PI3K/AKT/mTOR pathway changes, other targeted trials might apply.

Device-Based and Metabolic Combination Trials

Tumor Treating Fields (TTFields) are FDA-approved for glioblastoma and have been studied in recurrent grade III astrocytoma. The NOVOTTF-200A trial (NCT03450850) tested this device-based approach in bevacizumab-naive recurrent grade III patients and checked whether molecular markers (IDH1 mutation, ATRX loss, TERT promoter mutation, and MGMT methylation) predicted better TTFields response. Results posted in 2025 help show which molecular groups may respond best to device-based therapy.

On the metabolic side, the IDH mutation creates a weakness in glutamine metabolism. Telaglenastat, a glutaminase inhibitor, has been studied with radiation and temozolomide in IDH-mutated astrocytoma. These combination trials use the metabolic consequence of the IDH mutation alongside standard chemoradiation.

The National Brain Tumor Society keeps a current list of trials. Their November 2024 through June 2025 trial update highlights several studies enrolling patients with high-grade IDH-mutant gliomas. Check for newer updates regularly, as new trials open frequently.

A Practical Framework for Searching ClinicalTrials.gov

Searching ClinicalTrials.gov can feel overwhelming. This step-by-step approach can help organize your search:

• Search by condition. Enter anaplastic astrocytoma or IDH mutant astrocytoma grade 3 in the conditions field.
• Filter by status. Set the recruitment filter to Recruiting or Not yet recruiting.
• Match eligibility criteria to your pathology report. Look for required molecular markers and compare each one to your report. Print both documents side by side.
• Check the trial phase. Phase I tests safety and dosing. Phase II looks for early efficacy signals. Phase III compares a new approach directly to standard care. Earlier-phase trials may still be appropriate if other options are limited.
• Note prior treatment requirements. Many trials require a set number of prior treatment lines. Some enroll only newly diagnosed patients; others require documented recurrence.
• Identify the nearest enrolling site. ClinicalTrials.gov lists all participating institutions. Contact the study coordinator and principal investigator. The coordinator is usually fastest to tell you if spots are open.
• Ask your neuro-oncologist to pre-screen your profile. Share the NCT number and your molecular report before investing time in travel or remote consultations.

Matching Your Profile at Recurrence

When a grade III astrocytoma comes back after standard chemoradiation, the trials you can enter may change. Recurrent tumors that have not turned into grade IV may still qualify for IDH-targeted and immunotherapy trials. If a new biopsy shows higher-grade features (necrosis, microvascular proliferation, or newly detected CDKN2A homozygous deletion), eligibility criteria will change and you need fresh molecular testing.

At recurrence, ask your team these questions:

• Has a new biopsy or resection confirmed your current molecular profile? Recurrent tumors sometimes pick up new changes (including PIK3CA mutation or EGFR amplification) that change grade or trial eligibility.
• Has MGMT methylation status been re-evaluated? In a small number of cases it may shift after treatment.
• Has the tumor stayed as IDH-mutant astrocytoma, or does the recurrence pathology show a change to a different type?

How to Advocate Effectively for Trial Access

Getting into the right trial takes more than searching one database. These strategies can help:

• Request your complete molecular report. Community hospitals sometimes use limited panels with just a handful of markers. A comprehensive next-generation sequencing panel at an academic center might find additional changes that open new trial doors.
• Ask about tissue banking. Many trials require fresh or archived tumor tissue for research. Banking tissue at the time of surgery or resection keeps this option available for future studies.
• Contact brain tumor advocacy organizations. Both the National Brain Tumor Society and the American Brain Tumor Association (abta.org) offer trial-matching resources and patient navigators who can help find open studies that match your profile.
• Consider a second opinion at an NCI-designated cancer center. These centers run research studies and may have access to trials not available in community settings. A second opinion works alongside your current care team and usually improves the conversation.
• Start the inquiry early. Some trials have limited enrollment slots or close sooner than projected. Beginning conversations before you finish standard treatment keeps your options open.

When to Talk to Your Doctor

Bring up clinical trial options with your neuro-oncologist at diagnosis, during treatment, and at any sign of recurrence. Early conversations matter because some trials require enrollment at specific treatment milestones. If your center does not have open trials that match your molecular profile, ask for a referral to an academic medical center or NCI-designated cancer center. Bring a copy of your full molecular pathology report to any trial inquiry consultation.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.